Vontobel Holding Ltd. Invests $1.31 Million in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Vontobel Holding Ltd. purchased a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 43,540 shares of the biotechnology company's stock, valued at approximately $1,305,000.

A number of other large investors have also modified their holdings of the business. WCM Investment Management LLC grew its stake in shares of Rocket Pharmaceuticals by 2.5% during the fourth quarter. WCM Investment Management LLC now owns 296,013 shares of the biotechnology company's stock worth $9,147,000 after acquiring an additional 7,212 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Rocket Pharmaceuticals by 17.6% during the fourth quarter. Arizona State Retirement System now owns 18,864 shares of the biotechnology company's stock worth $565,000 after acquiring an additional 2,828 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Rocket Pharmaceuticals by 404.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,424 shares of the biotechnology company's stock worth $312,000 after acquiring an additional 8,356 shares during the last quarter. Harbour Capital Advisors LLC purchased a new stake in shares of Rocket Pharmaceuticals during the fourth quarter worth about $282,000. Finally, Citigroup Inc. grew its stake in shares of Rocket Pharmaceuticals by 87.2% during the third quarter. Citigroup Inc. now owns 161,115 shares of the biotechnology company's stock worth $3,301,000 after acquiring an additional 75,071 shares during the last quarter. Hedge funds and other institutional investors own 98.39% of the company's stock.

Insider Transactions at Rocket Pharmaceuticals

In other news, Director David P. Southwell sold 10,000 shares of the company's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $24.05, for a total transaction of $240,500.00. Following the completion of the transaction, the director now directly owns 114,784 shares of the company's stock, valued at approximately $2,760,555.20. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider John Militello sold 2,490 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $28.10, for a total value of $69,969.00. Following the completion of the transaction, the insider now directly owns 55,239 shares of the company's stock, valued at approximately $1,552,215.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David P. Southwell sold 10,000 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $24.05, for a total value of $240,500.00. Following the completion of the transaction, the director now directly owns 114,784 shares of the company's stock, valued at $2,760,555.20. The disclosure for this sale can be found here. Insiders sold a total of 414,740 shares of company stock valued at $11,474,727 in the last three months. 31.10% of the stock is currently owned by company insiders.

Rocket Pharmaceuticals Stock Performance

Rocket Pharmaceuticals stock traded down $0.68 during mid-day trading on Friday, hitting $22.80. The company had a trading volume of 960,831 shares, compared to its average volume of 569,443. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.04. Rocket Pharmaceuticals, Inc. has a 12-month low of $14.89 and a 12-month high of $32.53. The company's fifty day moving average is $27.20 and its 200-day moving average is $25.38. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -7.76 and a beta of 1.07.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its earnings results on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.14. During the same period last year, the company earned ($0.92) EPS. Equities research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.94 EPS for the current year.

Wall Street Analyst Weigh In

RCKT has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $53.00 target price on shares of Rocket Pharmaceuticals in a research report on Wednesday, April 10th. Lifesci Capital reiterated an "outperform" rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, December 26th. UBS Group dropped their target price on Rocket Pharmaceuticals from $56.00 to $54.00 and set a "buy" rating on the stock in a research report on Friday, March 1st. StockNews.com upgraded Rocket Pharmaceuticals to a "sell" rating in a research report on Friday, February 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $52.13.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.